Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer
The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). A range of preclinical safety and efficacy experiments will be performed to nominate a clinical candidate from a recently discovered and highly potent series of ERRa inhibitors. The new candidate drug will be supported by strong safety and efficacy data packages and be ready for clinical trials within 18 months after completion of the project.
3 645 440.00€
Pharmaceutical Products / Drugs
Drug delivery and other equipment (including kidney dialysis machines)